Med Biogene Inc (CVE:MBI) hit a new 52-week low during trading on Monday . The stock traded as low as C$0.05 and last traded at C$0.05, with a volume of 7000 shares. The stock had previously closed at C$0.05.

TRADEMARK VIOLATION NOTICE: “Med Biogene (MBI) Reaches New 12-Month Low at $0.05” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/11/14/med-biogene-mbi-reaches-new-12-month-low-at-0-05.html.

Med Biogene Company Profile (CVE:MBI)

Med BioGene Inc, a life science company, focuses on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer. Its products include the GeneFx Lung, a gene expression-based test for early-stage non-small-cell lung cancer that assists in identifying patients for adjuvant chemotherapy.

See Also: What is the balance sheet?

Receive News & Ratings for Med Biogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Med Biogene and related companies with MarketBeat.com's FREE daily email newsletter.